Due to improving treatment options, the number of so-called long-term cancer survivors is steadily increasing. Current studies assume that more than 60% of adults survive their cancer. These patients have a variety of problems (chemotherapy-induced neuropathy, fatigue, etc.) that require very special care. In addition to somatic and psychological side effects of the cancer or its treatment, these patients also suffer from the financial and social consequences of the disease. Thus, for a long-term survivor of working age, the question of a ‘return to work' represents a significant problem since otherwise the financial existence of the patient, and often the family, may substantially deteriorate. Studies show that cancer patients classify financial worries with regard to the quality of life as more significant than physical or psychological side effects of the cancer or its treatment. Furthermore, there are initial studies showing that the social descent due to the disease may also prove relevant for cancer prognosis. In contrast, it was shown in studies and in a Cochrane analysis that professional assistance and support services are suitable for keeping patients in their professional lives. Therefore, both patients and physicians need to be aware of this problem.

Keywords:
Long-term survivor, Return to work, Quality of life, Work-related medical rehabilitation, MBOR
1.
La Vecchia C, Rota M, Malvezzi M, Negrib E: Potential for improvement in cancer management: reducing mortality in the European Union. Oncologist 2015;20:495-498.
2.
Rick O, Kalusche EM, Dauelsberg T, König V, Korsukewitz C, Seitart U: Reintegrating cancer patients into the workplace. Dtsch Arztebl 2012;109:702-708.
3.
de Boer AG, Taskila T, Ojajärvi A, van Dijk FJ, Verbeek JH: Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 2009;301:753-762.
4.
Mehnert A: Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol 2011;77:109-130.
5.
Verbeek J, Spelten E, Kammeijer M, Sprangers M: Return to work of cancer survivors: a prospective cohort study into the quality of rehabilitation by occupational physicians. Occup Environ Med 2003;60:352-357.
6.
Short PF, Vasey JJ, Tuncelli K: Employment pathways in a large cohort of adult cancer survivors. Cancer 2005;103:1292-1301.
7.
Nieuwenhuijsen K, Bos-Ransdorp B, Uitterhoeve LL, Sprangers MA, Verbeek JH: Enhanced provider communication and patient education regarding return to work in cancer survivors following curative treatment: a pilot study. J Occup Rehabil 2006;16:647-657.
8.
Guy GP Jr, Ekwueme DU, Yabroff KR, Dowling EC, Li C, Rodriguez JL, de Moor JS, Virgo KS: Economic burden of cancer survivorship among adults in the United States. J Clin Oncol 2013;31:3749-3757.
9.
Jagsi R, Pottow AE, Griffith KA, Bradley C, Graff JH, Katz SJ, Hawley S: Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32:1269-1276.
10.
Delgado-Guay MO: Frequency, intensity, and correlates of financial distress (FD) among advanced cancer patients (AdCa). J Clin Oncol 2014;32(suppl 5):abstr 9635.
11.
Bansal A, Ramsey SD, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, Newcomb PA: Financial insolvency as a risk factor for mortality among patients with cancer. J Clin Oncol 2015;33(suppl):abstr 6509.
12.
Perrone F, Jommi C, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, et al.: The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Ann Oncol 2016;27:2224-2229.
13.
de Boer AG, Taskila TK, Tamminga SJ, Feuerstein M, Frings-Dresen MH, Verbeek JH: Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev 2015;(9):CD007569.
14.
Seifart U, Bohnenkamp H, Jackisch C: Armut durch Krebs - warum? Welche Krebspatienten sind als Folge der Krebserkrankung durch Armut bedroht? Hess Arztebl 2016;(3):145-147.
15.
Bethge M, Radoschewski FM, Spyra S: Risikoindex - Erwerbsminderungsrente (RI-EMR). Abschlussbericht zum durch Zuwendung nach Paragraph 31 Abs. 1 Nr. 5 SGB VI geförderten Bericht (Aktenzeichen 8011 - 106 - 31/31.27/14).
16.
Schultz PN, Beck ML, Stava C, Sellin RV: Cancer survivors work related issues. AAOHN J 2002;50:220-226.
17.
Syse A, Tretli S, Kravdal Ø: Cancer's impact on employment and earnings - a population-based study from Norway. J Cancer Surviv 2008;2:149-158.
18.
Taskila T, Lindbohm ML: Factors affecting cancer survivors' employment and work ability. Acta Oncol 2007;46:446-451.
19.
Kristinsson SY, Derolf AR, Edgren G, Dickman PW, Björkholm M: Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden. J Clin Oncol 2009;27:2073-2080.
20.
Spelten ER, Verbeek JH, Uitterhoeve AL, Ansink AC, van der Lelie J, de Reijke TM, et al.: Cancer, fatigue and the return of patients to work - a prospective cohort study. Eur J Cancer 2003;39:1562-1567.
21.
Taskila T, Martikainen R, Hietanen P, Lindbohm ML: Comparative study of work ability between cancer survivors and their referents. Eur J Cancer 2007;43:914-920.
22.
Bouknight RR, Bradley CJ, Luo Z: Correlates of return to work for breast cancer survivors. J Clin Oncol 2006;24:345-353.
23.
Taskila T, Lindbohm ML, Martikainen R, Lehto US, Hakanen J, Hietanen P: Cancer survivors' received and needed social support from their work place and the occupational health services. Support Care Cancer 2006;14:427-435.
24.
Böttcher HM, Steimann M, Koch U, Bergelt C: Rückkehr zur Arbeit - Erfahrungen und Erwartungen von Patientinnen und Patienten in der stationären onkologischen Rehabilitation. Rehabilitation 2012;51:31-38.
25.
Streibelt M, Buschmann-Steinhage R: [A profile of requirements for the performance of work related medical rehabilitation from the perspective of the statutory pension insurance]. Rehabilitation 2011;50:160-167.
26.
Bürger W, Deck R: [SIBAR - a short screening instrument for the assessment of need for occupation related treatment in medical rehabilitation]. Rehabilitation 2009;48:211-221.
27.
Böttcher HM, Steimann M, Ullrich A, Rotsch M, Zurborn KH, Koch U, et al.: [Evaluation of a vocationally oriented concept within inpatient oncological rehabilitation]. Rehabilitation 2013;52:329-336.
28.
Wienert J, Schwarz B, Bethge M: Effectiveness of work-related medical rehabilitation in cancer patients: study protocol of a cluster-randomized multicenter trial. BMC Cancer 2016;16:544.
29.
Wienert J, Schwarz B, Bethge M: [Medizinisch-beruflich orientierte Rehabilitation für onkologische Rehabilitanden - kurzfristige Ergebnisse einer clusterrandomisierten Multicenterstudie]. DRV Schr 2017;111:187-189.
30.
Böttcher HM, Steimann M, Ullrich A, Rotsch M, Zurborn KH, Koch U, et al.: Work-related predictors of not returning to work after inpatient rehabilitation in cancer patients. Acta Oncol 2013;52:1067-1075.
31.
Bürger W, Streibelt M: [What determines the participation in stepwise occupational reintegration on behalf of the German pension insurance? Results of the ‘SOR Cohort Study']. Rehabilitation 2015;54:10-15.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.